Permanently Discontinued

APO-LAMIVUDINE HBV

APOTEX INC

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is APO-LAMIVUDINE HBV discontinued in Canada?

Yes. The manufacturer has reported to Health Canada that APO-LAMIVUDINE HBV 100MG has been permanently discontinued (last updated December 21, 2019). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.

Why is APO-LAMIVUDINE HBV not available?

The reason the manufacturer reported: Business reasons.

Can I still get this?Possibly — same-ingredient product records found

StatusPermanently Discontinued

Same-ingredient products on file3 products · 2 same form & route

Affected strength100MG

Report last updated2019-12-21

Checked by MedShort2026-11-12

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

JAMP LAMIVUDINE HBV

JAMP PHARMA CORPORATION

100MG · DIN 02512467

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

Other Products

3TC

VIIV HEALTHCARE ULC

10MG · DIN 02192691

Different strengthDifferent dosage formSame routeNo current shortage

Compare these two →

JAMP LAMIVUDINE

JAMP PHARMA CORPORATION

150MG · DIN 02507110

Different strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean I need to switch medications right away?

Not necessarily right away, but this product will not be returning to the market.

What should I do?

Talk to your pharmacist or prescriber about your options well before your current supply runs out.

DIN

02393239

Strength

100MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

LAMIVUDINE

Tier

Unrated

Last Updated

2019-12-21

Reason for Shortage

Business reasons

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

APO-LAMIVUDINE HBV has 2 shortage/discontinuation reports on file — this is one of them.

2026-10-27

Resolved

Disruption of the manufacture of the drug.

Other Products from APOTEX INC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

24HR NASAL ALLERGY RELIEF

50MCG · DIN 02460513

ACETAMINOPHEN CAPLETS 325 MG

325MG · DIN 02362341

ACETAMINOPHEN CAPLETS 500 MG

500MG · DIN 02362368

ACETAMINOPHEN HEADACHE ULTRA RELIEF

DIN 02290901

ACETAMINOPHEN TABLETS USP 325 MG

325MG · DIN 02362422

ACETAMINOPHEN TABLETS USP 500 MG

500MG · DIN 02362244